Logo image of PSG.DE

PHARMASGP HOLDING SE (PSG.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:PSG - DE000A2P4LJ5 - Common Stock

29 EUR
0 (0%)
Last: 8/11/2025, 7:00:00 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to PSG. PSG was compared to 54 industry peers in the Pharmaceuticals industry. PSG scores excellent on profitability, but there are some minor concerns on its financial health. PSG is growing strongly while it is still valued neutral. This is a good combination! These ratings could make PSG a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year PSG was profitable.
  • PSG had positive earnings in each of the past 5 years.
  • In the past 5 years PSG always reported a positive cash flow from operatings.
PSG.DE Yearly Net Income VS EBIT VS OCF VS FCFPSG.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

  • PSG has a Return On Assets of 13.88%. This is amongst the best in the industry. PSG outperforms 88.46% of its industry peers.
  • PSG has a Return On Equity of 44.72%. This is amongst the best in the industry. PSG outperforms 90.38% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 19.34%, PSG belongs to the top of the industry, outperforming 86.54% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for PSG is significantly above the industry average of 13.93%.
  • The last Return On Invested Capital (19.34%) for PSG is well below the 3 year average (27.58%), which needs to be investigated, but indicates that PSG had better years and this may not be a problem.
Industry RankSector Rank
ROA 13.88%
ROE 44.72%
ROIC 19.34%
ROA(3y)10.34%
ROA(5y)17.96%
ROE(3y)42.62%
ROE(5y)47.56%
ROIC(3y)27.58%
ROIC(5y)38.56%
PSG.DE Yearly ROA, ROE, ROICPSG.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

1.3 Margins

  • With a decent Profit Margin value of 16.22%, PSG is doing good in the industry, outperforming 63.46% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PSG has declined.
  • The Operating Margin of PSG (24.37%) is better than 61.54% of its industry peers.
  • PSG's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 90.64%, PSG belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PSG has remained more or less at the same level.
Industry RankSector Rank
OM 24.37%
PM (TTM) 16.22%
GM 90.64%
OM growth 3Y1.74%
OM growth 5Y-5.45%
PM growth 3Y-1.21%
PM growth 5Y-7.78%
GM growth 3Y0.17%
GM growth 5Y0.3%
PSG.DE Yearly Profit, Operating, Gross MarginsPSG.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

  • PSG has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for PSG remains at a similar level compared to 1 year ago.
  • PSG has a better debt/assets ratio than last year.
PSG.DE Yearly Shares OutstandingPSG.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
PSG.DE Yearly Total Debt VS Total AssetsPSG.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 4.90 indicates that PSG is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of PSG (4.90) is better than 76.92% of its industry peers.
  • PSG has a Debt/Equity ratio of 1.58. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.58, PSG is doing worse than 73.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Altman-Z 4.9
ROIC/WACC2.91
WACC6.65%
PSG.DE Yearly LT Debt VS Equity VS FCFPSG.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that PSG has no problem at all paying its short term obligations.
  • The Current ratio of PSG (2.68) is better than 86.54% of its industry peers.
  • PSG has a Quick Ratio of 2.24. This indicates that PSG is financially healthy and has no problem in meeting its short term obligations.
  • PSG's Quick ratio of 2.24 is amongst the best of the industry. PSG outperforms 86.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.24
PSG.DE Yearly Current Assets VS Current LiabilitesPSG.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

  • PSG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.25%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 2.18% on average over the past years.
  • PSG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.80%.
  • Measured over the past years, PSG shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)37.25%
EPS 3Y15.53%
EPS 5Y2.18%
EPS Q2Q%7.89%
Revenue 1Y (TTM)17.8%
Revenue growth 3Y16.92%
Revenue growth 5Y10.78%
Sales Q2Q%10.81%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.27% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 9.65% on average over the next years. This is quite good.
EPS Next Y28.05%
EPS Next 2Y23.3%
EPS Next 3Y20.27%
EPS Next 5YN/A
Revenue Next Year15.62%
Revenue Next 2Y11.7%
Revenue Next 3Y10.35%
Revenue Next 5Y9.65%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PSG.DE Yearly Revenue VS EstimatesPSG.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M
PSG.DE Yearly EPS VS EstimatesPSG.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 21.17, which indicates a rather expensive current valuation of PSG.
  • PSG's Price/Earnings is on the same level as the industry average.
  • PSG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
  • PSG is valuated correctly with a Price/Forward Earnings ratio of 15.35.
  • The rest of the industry has a similar Price/Forward Earnings ratio as PSG.
  • PSG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.30, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 21.17
Fwd PE 15.35
PSG.DE Price Earnings VS Forward Price EarningsPSG.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • PSG's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.32
PSG.DE Per share dataPSG.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PSG has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as PSG's earnings are expected to grow with 20.27% in the coming years.
PEG (NY)0.75
PEG (5Y)9.72
EPS Next 2Y23.3%
EPS Next 3Y20.27%

More info and screens

2

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.76%, PSG has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.59, PSG has a dividend in line with its industry peers.
  • PSG's Dividend Yield is comparable with the S&P500 average which is at 1.86.
Industry RankSector Rank
Dividend Yield 1.76%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
PSG.DE Yearly Dividends per sharePSG.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DP0%
EPS Next 2Y23.3%
EPS Next 3Y20.27%
PSG.DE Yearly Income VS Free CF VS DividendPSG.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

More info and screens

PHARMASGP HOLDING SE

FRA:PSG (8/11/2025, 7:00:00 PM)

29

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15
Earnings (Next)09-11
Inst Owners1.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap348.00M
Revenue(TTM)101.10M
Net Income(TTM)16.40M
Analysts80
Price Target38.76 (33.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.76%
Yearly Dividend0.49
Dividend Growth(5Y)N/A
DP0%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.94%
PT rev (3m)-1.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 21.17
Fwd PE 15.35
P/S 3.44
P/FCF N/A
P/OCF N/A
P/B 9.49
P/tB N/A
EV/EBITDA 11.32
EPS(TTM)1.37
EY4.72%
EPS(NY)1.89
Fwd EY6.51%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.42
BVpS3.06
TBVpS-1.68
PEG (NY)0.75
PEG (5Y)9.72
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 13.88%
ROE 44.72%
ROCE 25.69%
ROIC 19.34%
ROICexc 27.86%
ROICexgc 190.83%
OM 24.37%
PM (TTM) 16.22%
GM 90.64%
FCFM N/A
ROA(3y)10.34%
ROA(5y)17.96%
ROE(3y)42.62%
ROE(5y)47.56%
ROIC(3y)27.58%
ROIC(5y)38.56%
ROICexc(3y)247.79%
ROICexc(5y)251.02%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)36.65%
ROCE(5y)51.23%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-53.62%
ROICexc growth 5Y-31.79%
OM growth 3Y1.74%
OM growth 5Y-5.45%
PM growth 3Y-1.21%
PM growth 5Y-7.78%
GM growth 3Y0.17%
GM growth 5Y0.3%
F-ScoreN/A
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Debt/EBITDA 1.71
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.24
Altman-Z 4.9
F-ScoreN/A
WACC6.65%
ROIC/WACC2.91
Cap/Depr(3y)784.53%
Cap/Depr(5y)529.48%
Cap/Sales(3y)43.17%
Cap/Sales(5y)26.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.25%
EPS 3Y15.53%
EPS 5Y2.18%
EPS Q2Q%7.89%
EPS Next Y28.05%
EPS Next 2Y23.3%
EPS Next 3Y20.27%
EPS Next 5YN/A
Revenue 1Y (TTM)17.8%
Revenue growth 3Y16.92%
Revenue growth 5Y10.78%
Sales Q2Q%10.81%
Revenue Next Year15.62%
Revenue Next 2Y11.7%
Revenue Next 3Y10.35%
Revenue Next 5Y9.65%
EBIT growth 1Y38.59%
EBIT growth 3Y18.96%
EBIT growth 5Y4.74%
EBIT Next Year36.09%
EBIT Next 3Y17%
EBIT Next 5Y15.17%
FCF growth 1Y7.72%
FCF growth 3Y20.97%
FCF growth 5Y25.88%
OCF growth 1Y7.79%
OCF growth 3Y19.89%
OCF growth 5Y25.88%

PHARMASGP HOLDING SE / PSG.DE FAQ

Can you provide the ChartMill fundamental rating for PHARMASGP HOLDING SE?

ChartMill assigns a fundamental rating of 6 / 10 to PSG.DE.


What is the valuation status of PHARMASGP HOLDING SE (PSG.DE) stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMASGP HOLDING SE (PSG.DE). This can be considered as Fairly Valued.


What is the profitability of PSG stock?

PHARMASGP HOLDING SE (PSG.DE) has a profitability rating of 8 / 10.


What is the financial health of PHARMASGP HOLDING SE (PSG.DE) stock?

The financial health rating of PHARMASGP HOLDING SE (PSG.DE) is 6 / 10.


Is the dividend of PHARMASGP HOLDING SE sustainable?

The dividend rating of PHARMASGP HOLDING SE (PSG.DE) is 2 / 10 and the dividend payout ratio is 0%.